BioVaxys Lowers Private Placement Unit Price and Expands Offering

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Dec. 11, 2024 /CNW/ —  BioVaxys Technology Corp. BIOV 5LB (“BioVaxys” or the “Company“) has announced a decrease in the price of its Units for the recent private placement (“Offering“), which was initially revealed on November 18, 2024. In tandem, the number of Units available has also been increased.

The price per Unit has dropped from $0.07 to $0.05. The goal to raise $1,000,000 remains intact, leading to an increase in the total Units from 14,285,715 to 20,000,000.

Each Unit consists of one common share (“Share“) along with a purchase warrant (“Warrant“). Each Warrant allows the holder to buy an additional Share at a price of $0.15 over a period of 24 months from issuance.

The funds generated from this Offering will be used primarily for working capital, with the potential to pay finder’s fees associated with the Offering.

Securities issued will face a hold period of four months and one day after issuance, according to relevant securities laws. The Offering’s closing is contingent upon receiving all necessary regulatory approvals, including those from the Canadian Securities Exchange.

This announcement is not an invitation to buy or sell securities in the United States. The securities issued have not been registered under the U.S. Securities Act of 1933, and cannot be sold in the U.S. unless registered or qualifying for an exemption.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company based in British Columbia, Canada. They focus on developing innovative immunotherapies using the DPX™ immune-educating technology and the HapTenix© ‘neoantigen’ tumor cell construct platform. These therapies target cancer, infectious diseases, antigen desensitization, and various immunological issues. The DPX™ platform, which is patented, offers a way to deliver antigens to lymph nodes, producing effective immune responses demonstrated in both pre-clinical and clinical trials. BioVaxys shares trade on the Canadian Securities Exchange under the symbol “BIOV”, on the Frankfurt Bourse as 5LB, and are quoted in the U.S. OTC Markets. More information can be found at www.biovaxys.com and through their social media profiles on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 740 358 0555

Cautionary Statements Regarding Forward Looking Information

This release contains “forward-looking information” and “forward-looking statements” as defined in securities legislation. These include statements about the Offering, its size, intended use of the proceeds, and the Company’s ability to close the Offering pending regulatory approval. Such statements often use phrases like “expects”, “anticipates”, “believes”, or “may”. There is no guarantee these predictions will be accurate, as actual outcomes may differ significantly. Factors affecting these outcomes may include completion of the Offering and obtaining necessary approvals. BioVaxys assumes no responsibility for updating forward-looking statements unless required by law.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release and does not accept any responsibility for its accuracy or adequacy.

Logo: https://mma.prnewswire.com/media/2415135/5062063/BioVaxys_Technology_Corp_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/biovaxys-announces-repricing-of-private-placement-offering-302328524.html

SOURCE BioVaxys Technology Corp.

View original content: http://www.newswire.ca/en/releases/archive/December2024/11/c6163.html